Correlation between protein YKL-40 and ultrasonographic findings in active knee osteoarthritis

Karalilova, Rositsa; Kazakova, Maria; Batalov, Anastas; Sarafian, Victoria

doi:10.11152/mu-1247

Cited by 18 publications

(11 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Endstage HOA/KOA patients have increased levels of oxidative stress markers, decreased antioxidant capacity, impaired lipid metabolism, and dysglycemia 34 . Moreover, glycoprotein YKL-40, a potential marker for active inflammatory process, is involved in the pathogenesis of KOA synovitis 35 . Patients with early-and late-stage posttraumatic KOA have increased levels of circulating proinflammatory NOx and IL-6 compared with healthy controls (HCs) and KOA severity was correlated with leptin levels in both plasma (P) and SF 36 .…”

Section: Association With Clinical Scores and Changesmentioning

confidence: 99%

Osteoarthritis year in review 2018: biomarkers (biochemical markers)

Hosnijeh

Bierma-Zeinstra

Bay‐Jensen

2019

Osteoarthritis and Cartilage

View full text Add to dashboard Cite

The aim of this narrative review is to summarize important findings from biochemical marker studies relevant to osteoarthritis (OA) in the context of new discoveries and clinical and scientific need. Design: We conducted a systematic search of electronic medical databases (Embase, Medline, Web of Science, Cochrane central) between 01-03-2017 and 31-03-2018. The search was restricted to human studies, English language and full text available publications while reviews were excluded. Only papers describing protein based biomarkers measured in human body fluids (blood, urine and synovial fluid (SF)) were included. Of the 992 papers, 86 were reviewed here, with inclusion primarily based on relevance to OA biochemical markers. Results: This review highlights a selection of studies based on their quality and perceived importance to the field mainly including those that 1 evaluate prognostic value of biomarkers for OA progression (i.e., biomarkers reflecting change in composition of joint tissues and biomarkers of inflammation) 2 , help in assessment of intervention efficacy, and 3 are innovative and uncover new candidate biomarkers, or use new approaches in biomarker discovery. Conclusions: Key findings and implications for possible clinical utility of biochemical markers are summarized and discussed. Given the paucity of robust biomarkers within the field, and the heterogeneity of the condition, enormous works are needed for development and validation of novel and clinically applicable biomarkers to reduce the impact of this highly prevalent and debilitating condition.

show abstract

Section: Association With Clinical Scores and Changesmentioning

confidence: 99%

Osteoarthritis year in review 2018: biomarkers (biochemical markers)

Hosnijeh

Bierma-Zeinstra

Bay‐Jensen

2019

Osteoarthritis and Cartilage

View full text Add to dashboard Cite

show abstract

“…12 CHI3L1 is secreted by macrophages, synoviocytes, and chondrocytes, [13][14][15][16] and can be detected at increased levels in the synovial fluid and serum of patients with inflammatory conditions, in addition to correlating with the extent of joint degradation in rheumatoid arthritis (RA) patients. 17 Inhibiting CHI3L1 has previously been shown to suppress inflammation and cortical bone degeneration in a murine osteomyelitis model system, 18 while Kim et al 19 similarly determined that knocking down this glycoprotein protected against hyperoxia-induced apoptotic death in human airway epithelial cells, whereas CHI3L1 overexpression increased the susceptibility of these cells to such apoptosis. As such, these prior data highlight CHI3L1 as an important regulator of inflammatory and oxidative stress responses.…”

Section: Introductionmentioning

confidence: 99%

Nrf2 Regulates CHI3L1 to Suppress Inflammation and Improve Post-Traumatic Osteoarthritis

Song¹,

Hao²,

Jiang³

et al. 2021

JIR

View full text Add to dashboard Cite

Introduction: Post-traumatic osteoarthritis (PTOA) is an inflammatory condition that occurs following mechanical joint trauma and that results in joint degeneration. This study sought to evaluate the regulatory function of nuclear factor erythroid 2-related factor 2 (Nrf2) in a murine model of anterior cruciate ligament transection (ACLT)-induced PTOA and in an in vitro model of synoviocyte inflammation induced by LPS treatment with the goal of exploring the role of chitinase 3-like-1 (CHI3L1) in this pathogenic context. Methods: PTOA model mice were intra-articularly injected with Nrf2 overexpression lentiviral vector, and safranin O-fast green staining as well as the Osteoarthritis Research Society International (OARSI) Scoring System were used to evaluate the severity of cartilage damage. Protein expression in the synovial tissue was evaluated by Western blotting, immunohistochemical staining, and ELISA. Additionally, murine synoviocytes were infected with Nrf2 overexpression lentivirus and stimulated with LPS. The levels of inflammatory cytokines were detected by ELISA. ROS levels were measured using dihydroethidium (DHE) dye. Results: We determined that the overexpression of Nrf2 was sufficient to reduce cartilage degradation in the context of PTOA in vivo, and we observed a significant decrease in the expression of matrix metalloproteinase 13 (MMP13) in the articular cartilage of samples from mice overexpressing Nrf2 relative to control mice. Synovial CHI3L1 expression and serum TNF-α, IL-1β, and IL-6 levels were reduced in animals overexpressing this transcription factor relative to PTOA model controls. Consistent with these findings, murine synoviocytes treated with LPS exhibited dose-dependent increases in ROS, TNF-α, IL-1β, IL-6, Nrf2, and CHI3L1 levels, whereas Nrf2 overexpression was sufficient to suppress these increases. Conclusion:Our data indicated that Nrf2 negatively regulates CHI3L1, suggesting that this signaling axis may regulate PTOA progression and may thus be a viable therapeutic target in individuals affected by this condition.

show abstract

“…It can be detected in urine, blood, and synovial fluid (7). YKL-40 is a member of the 18 glycosyl hydrolase family and is widely distributed in synoviocytes and chondrocytes (8). Studies have shown that CTX-II and YKL-40 are closely related to the pathological changes of articular cartilage and can reflect the degree of inflammation of OA (9).…”

Section: Introductionmentioning

confidence: 99%

CTX‑II and YKL‑40 in early diagnosis and treatment evaluation of osteoarthritis

2018

View full text Add to dashboard Cite

This study investigated the value of C-terminal telopeptides of collagen type II (CTX-II) and YKL-40 in early diagnosis and treatment evaluation of osteoarthritis (OA). A total of 90 patients with OA diagnosed and treated in The First Affiliated Hospital, Guangzhou Medical University from March 2015 to January 2018 were selected as the study group. At the same time, 50 healthy elderly were included as the control group. The study group was divided into three subgroups including group A (29 cases, 500 mg glucosamine sulfate), group B (29 cases, 50 mg diacerein) and group C (32 cases, 500 mg glucosamine sulfate and 50 mg diacerein). Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) was used to assess the severity and treatment of arthritis. Enzyme-linked immunosorbent assay was used to measure the concentration of CTX-II and YKL-40 in serum. WOMAC scores in the study A, B and C groups were significantly higher than those in the control group (P<0.001). Serum CTX-II and YKL-40 concentrations were higher in the study group than in the control group (P<0.001). Sensitivity of serum CTX-II combined with YKL-40 in the diagnosis of OA was 90% and the specificity was 78%. CTX-II and YKL-40 levels in different Kellgren Lawrence (K-L) grades were significantly different (P<0.001), and increased with the increase of K-L grade. Concentrations of serum CTX-II and YKL-40 before treatment in the study group was positively correlated with WOMAC score (P<0.001). At 3, 6 and 9 weeks after the beginning of treatment, serum concentrations of CTX-II and YKL-40 decreased significantly (P<0.001). At 3 weeks of treatment, CTX-II was positively correlated with YKL-40 concentration and WOMAC score (r=0.406, P<0.001; r=0.430, P<0.001); CTX-II was positively correlated with YKL-40 concentration and WOMAC score at 6 weeks of treatment (r=0.350, P<0.001; r=0.358, P<0.001); CTX-II was positively correlated with YKL-40 concentration and WOMAC score at 9 weeks after treatment (r=0.370, P<0.001; r=0.394, P<0.001). Combined detection of serum CTX-II and YKL-40 can improve the sensitivity of early OA diagnosis, and it has an important diagnostic value for early OA patients. Therefore, it can be used as a biological indicator for early OA diagnosis, severity assessment, and evaluation of treatment effects.

show abstract

Correlation between protein YKL-40 and ultrasonographic findings in active knee osteoarthritis

Cited by 18 publications

References 31 publications

Osteoarthritis year in review 2018: biomarkers (biochemical markers)

Osteoarthritis year in review 2018: biomarkers (biochemical markers)

Nrf2 Regulates CHI3L1 to Suppress Inflammation and Improve Post-Traumatic Osteoarthritis

CTX‑II and YKL‑40 in early diagnosis and treatment evaluation of osteoarthritis

Contact Info

Product

Resources

About